Search

Kelvin K Yen

from Santa Monica, CA
Age ~46

Kelvin Yen Phones & Addresses

  • 849 14Th St APT 2, Santa Monica, CA 90403 (424) 256-2409
  • Menlo Park, CA
  • Mountain View, CA
  • 2570 Cedar St, Berkeley, CA 94708
  • 175 96Th St, New York, NY 10128
  • 245 93Rd St, New York, NY 10128
  • Los Angeles, CA
  • Northborough, MA
  • Sunnyvale, CA

Resumes

Resumes

Kelvin Yen Photo 1

Research Assistant Professor

View page
Location:
10417 Louisiana Ave, Los Angeles, CA 90025
Industry:
Biotechnology
Work:
University of Southern California
Research Assistant Professor

University of Southern California Aug 2012 - Oct 2013
Postdoctoral Scholar

Ucla Jan 2012 - Aug 2012
Postdoctoral Scholar

Umass Medical School Apr 2008 - Dec 2011
Post-Doctoral Associate

Icahn School of Medicine at Mount Sinai 2001 - 2008
Graduate Student
Education:
Icahn School of Medicine at Mount Sinai 2002 - 2007
Doctorates, Doctor of Philosophy, Neuroscience
University of California, Berkeley 1995 - 1999
Bachelors, Bachelor of Arts, Molecular Biology
Skills:
Fluorescence Microscopy
Western Blotting
Cell Culture
Cell Biology
Molecular Biology
Pcr
Qpcr
Biochemistry
Immunofluorescence
Rna Isolation
Molecular Cloning
Tissue Culture
Protein Chemistry
Transfection
Genetics
Stem Cells
Life Sciences
Research
Kelvin Yen Photo 2

Kelvin Yen

View page

Publications

Us Patents

Mentsh Analogs As Therapeutics For Diabetes, Obesity, And Their Associated Diseases And Complications

View page
US Patent:
20190194275, Jun 27, 2019
Filed:
Jun 23, 2017
Appl. No.:
16/311599
Inventors:
- Los Angeles CA, US
Kelvin Yen - Los Angeles CA, US
Assignee:
University of Southern California - Los Angeles CA
International Classification:
C07K 14/47
G01N 33/68
A61P 3/04
A61P 3/10
Abstract:
Described herein is a novel, mitochondrial encoded, open reading frame, that leads to the production of a new mitochondrial peptide. Residing within the ND-Two subunit, a specific small nucleotide polymorphism disrupts expression of this mitochondrial peptide, and is correlated with an increase in obesity and diabetes, particularly in certain ethnic populations. In vitro administration of the peptide increases insulin secretion, decreases fat accumulation and improves glucose uptake in muscle cell. Antibodies generated against the peptide can be used for detecting peptide deficiency, in addition to SNP detection, supporting diagnostic approaches. In vivo studies further revealed that administration of the peptide improves glucose tolerance, thereby providing a new therapeutic avenue for a novel diabetes therapy and decreases bodyweight, thus serving as a novel obesity therapy. Generation of synthetic analogs further enhance or abrogated activity relative to the natural peptide.
Kelvin K Yen from Santa Monica, CA, age ~46 Get Report